T1	Treatment 25 35	evolocumab
T2	Treatment 125 143	placebo-controlled
T3	Treatment 443 453	Evolocumab
T4	Treatment 457 476	monoclonal antibody
T5	Treatment 480 525	proprotein convertase subtilisin/kexin type 9
T6	Treatment 611 621	evolocumab
T7	Treatment 653 671	placebo-controlled
T8	Treatment 726 744	placebo-controlled
T9	Treatment 952 986	on stable lipid-regulating therapy
T10	Treatment 1139 1188	receive subcutaneous evolocumab 420 mg or placebo
T11	Treatment 1323 1374	by a computerised interactive voice-response system
T12	Treatment 1979 1990	the placebo
T13	Treatment 2007 2021	the evolocumab
T14	Treatment 2039 2063	with placebo, evolocumab
T15	Treatment 2246 2261	patients in the
T16	Treatment 2292 2312	33 in the evolocumab
T17	Treatment 2383 2401	no anti-evolocumab
T18	Treatment 2592 2613	apheresis, evolocumab
T19	Treatment 2709 2722	compared with
